Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: Galirayo who wrote (2135)	11/20/2000 8:52:10 PM
From: scaram(o)uche	Respond to of 4974

It's been a concerted effort. This time, at least Robbie Stephens has made some supportive noises along the trail. In March, the underwriters had just issued a slug of mega over-valued paper before standing back, silent. But, again, I agree with Gruss, Gruel, Barfholder et al.... the highflyers had a lot of justifiable ground to recover. The only think that I want is to see people name stocks, rather than damn a wide variety of disciplines in one swath. They can't do it, so they don't try. One exception was Gruss.... they game some names, but the names (IMNX, BGEN) held up relatively well until today, and even then they didn't come unglued. I haven't felt much pain down in "ignored, under-valued land". However, I've done my usual..... sunk dry powder into stuff that won't bounce big, watching the big bouncers come back, posturing for a retrace. Sigh. But, there's one good thing about this.... while I won't have dry powder to participate, it's soon be...... Ray time! <g> Credit where credit is due..... Motley Fool was first to put the "it's biotech's turn" into the spotlight. Credit where credit is due..... the Motley Fool slam was lame.